SCHEDULE 13G: BlackRock Discloses 5.0% Passive Stake in Compass Therapeutics
Beneficial Ownership Report
BlackRock, Inc. has filed a Schedule 13G, reporting a 5.0% beneficial ownership stake in Compass Therapeutics, Inc. as of December 31, 2024.
Summary
- BlackRock, Inc. has filed a Schedule 13G with the U.S. Securities and Exchange Commission (SEC), disclosing its beneficial ownership in Compass Therapeutics, Inc.
- As of December 31, 2024, BlackRock beneficially owns an aggregate of 6,887,615 shares of Compass Therapeutics, Inc. common stock.
- This ownership represents 5.0% of the total outstanding common stock of Compass Therapeutics, Inc.
- BlackRock holds sole voting power over 6,761,765 shares and sole dispositive power over 6,887,615 shares.
- The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- The filing was made by BlackRock, Inc. as a parent holding company, with various subsidiaries having beneficial ownership, including BlackRock Advisors, LLC, BlackRock Investment Management (UK) Limited, and BlackRock Fund Advisors.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, providing no positive or negative operational or financial news about the issuer. The sentiment is neutral.
Future Outlook
NA
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
This filing indicates a significant passive investment by a major institutional asset manager, BlackRock, in a biotechnology company, Compass Therapeutics, Inc. Such disclosures are common for large asset managers as their holdings cross regulatory thresholds, reflecting their broad market exposure rather than specific strategic moves related to the issuer's industry trends.
Stakeholder Impact
- Shareholders of Compass Therapeutics, Inc. are informed of a significant passive ownership stake by BlackRock, Inc., a major institutional investor, which may be viewed as a vote of confidence in the company's long-term prospects by a large asset manager.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney date, which was expressly revoked by the new Power of Attorney. |
| 2024-12-31 | Date of event which requires the filing of this statement, indicating the beneficial ownership stake. |
| 2025-01-21 | Date of the new Power of Attorney document executed by BlackRock, Inc. |
| 2025-02-04 | Signature date of the Schedule 13G filing by BlackRock, Inc. |
Keywords
BlackRock, Compass Therapeutics Inc., Schedule 13G, beneficial ownership, common stock, institutional investor, passive investment, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.